Pharmaceutical giant Eli Lilly has discovered a potential secondary benefit of their weight loss drug, Zepbound. The medication could also reduce the risk of heart failure, according to recent clinical trials. Further research is currently being conducted by the company.
McDonald’s is catching attention with their new menu item, the “Big Arch,” a juicy double-patty burger with a distinctive tangy sauce. The item is part of McDonald’s efforts to innovate their menu and the company is eager to see customers’ response.
The airline industry is seeing significant changes. Spirit Airlines is restructuring its fare system, moving away from its focus on affordability, while Southwest Airlines is expanding to more international destinations. The Paris Air Show saw Airbus outshine rival Boeing with strong sales figures, causing speculation of a leadership change in Boeing.
Eli Lilly’s drug and heart failure connection
Barry Diller, a notable Democrat and IAC executive, controversially called for the replacement of the FTC Chair, sparking debate and raising eyebrows due to an ongoing FTC investigation into one of his companies.
In other news, McDonald’s sales have dropped in Shanghai, attributed to inflation concerns. The company is devising strategies to recoup losses and appeal to customers. Insider sources suggest possible cost-cutting measures and new marketing strategies.
The California Department of Motor Vehicles has digitized 42 million vehicle titles in an effort to combat counterfeiting and auto fraud. The data is stored on Ava Labs’ secure Avalanche blockchain, with the implementation handled by technology giant Oxhead Alpha.
Lastly, Eli Lilly’s diabetes drug, Mounjaro, is already showing robust sales and demonstrating solid potential as an effective diabetes treatment. Conversely, well-known snack brands like Oreos, Doritos, and Kraft Mac & Cheese are seeing a dip in sales, possibly due to recent price increases. This suggests customer sensitivity towards price hikes could be affecting their purchasing decisions.
